BELLUS Health Inc
TSX:BLU

Watchlist Manager
BELLUS Health Inc Logo
BELLUS Health Inc
TSX:BLU
Watchlist
Price: 19.48 CAD -0.1% Market Closed
Market Cap: 2.5B CAD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

There is not enough data to reliably calculate the relative value of BLU.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BLU Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

120 096.9
P/S
P/S
Price to Sales
120 096.9
vs History
vs Industry
Median 3Y
118 744.7
Median 5Y
72 165.5
Industry
7.6
Forward
151 797.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-17.8
Industry
24.2
Forward
-16.9
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-20.1
Median 5Y
-19
Industry
20.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-20
Median 5Y
-19
Industry
22.9
More Details
4.9
P/B
P/B
Price to Book Value
4.9
vs History
vs Industry
Median 3Y
4.9
Median 5Y
4.7
Industry
2.9
More Details
99 286.6
EV/S
EV/S
Enterprise Value to Sales
99 286.6
vs History
vs Industry
Median 3Y
97 934.4
Median 5Y
54 219.7
Industry
7.9
Forward
125 493.9
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-16.3
Median 5Y
-13.3
Industry
5.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-16.3
Median 5Y
-13.2
Industry
5.1
Forward
-14.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-16.6
Median 5Y
-14.2
Industry
5.7
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-16.6
Median 5Y
-14.2
Industry
4.2
More Details
26.1
EV/IC
EV/IC
Enterprise Value to IC
26.1
vs History
vs Industry
Median 3Y
25.7
Median 5Y
18.6
Industry
5.2
More Details

Multiples Across Competitors

BLU Competitors Multiples
BELLUS Health Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
BELLUS Health Inc
TSX:BLU
2.5B CAD 120 096.9 -20.8 -16.6 -16.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 750 390.3 -160 410.6 -194 789.6 -192 566.9
US
Abbvie Inc
NYSE:ABBV
336.1B USD 5.9 80.9 15.4 22.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD 374 305.7 -13 141.6 -13 213.5 -13 207.5
US
Amgen Inc
NASDAQ:AMGN
164.8B USD 4.8 27.8 14.8 24.4
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD 5 24.3 10.5 14.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD 10.9 -122 26 27.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.4 -532.6 -580 -564.5
AU
CSL Ltd
ASX:CSL
129.7B AUD 5.6 31 19 23.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD 4.3 13.5 12.1 13.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.5 -60
P/S Multiple
Revenue Growth P/S to Growth
CA
BELLUS Health Inc
TSX:BLU
Average P/S: 3 113 357.9
120 096.9
439%
273.6
FR
Pharnext SCA
OTC:PNEXF
33 750 390.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
374 305.7
140%
2 673.6
US
Amgen Inc
NASDAQ:AMGN
4.8
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
5
3%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.9
10%
1.1
US
E
Epizyme Inc
F:EPE
2 087.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5.6
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.3
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
CA
BELLUS Health Inc
TSX:BLU
Average P/E: 35.5
Negative Multiple: -20.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 410.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.9
88%
0.9
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 141.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
27.8
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
24.3
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -122 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.6 N/A N/A
AU
CSL Ltd
ASX:CSL
31
16%
1.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
BELLUS Health Inc
TSX:BLU
Average EV/EBITDA: 16.3
Negative Multiple: -16.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 789.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 213.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
6%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580 N/A N/A
AU
CSL Ltd
ASX:CSL
19
11%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.1
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
BELLUS Health Inc
TSX:BLU
Average EV/EBIT: 21
Negative Multiple: -16.5 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 566.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.4
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
14.5
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.5 N/A N/A
AU
CSL Ltd
ASX:CSL
23.7
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60 N/A N/A

See Also

Summary
BLU intrinsic value, competitors valuation, and company profile.
DCF Valuation
BLU stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BLU stock valuation using valuation multiples.
Wall Street Estimates
BLU price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BLU stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 270,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.